Literature DB >> 20156505

Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis.

Orlando Torres1, Rogelio Palomino-Morales, Tomas R Vazquez-Rodriguez, Santos Castañeda, Inmaculada C Morado, Jose A Miranda-Filloy, Norberto Ortego-Centeno, Benjamin Fernandez-Gutierrez, Javier Martin, Miguel A Gonzalez-Gay.   

Abstract

Giant cell arteritis (GCA) is a complex polygenic disease in which more than one genetic locus is likely to contribute to disease susceptibility and clinical expression. In the present study, we have analyzed for first time the implication of rs13277113 and rs2736340 variants from the C8orf13-BLK gene region in the susceptibility to GCA. A total of 220 biopsy-proven GCA patients and 486 matched controls were assessed. DNA from patients and controls was obtained from peripheral blood. Samples were genotyped for the C8orf13-BLK region rs13277113 and rs2736340 using a predesigned TaqMan allele discrimination assay. No significant differences in the genotype distribution between GCA patients and controls for the rs13277113 and rs2736340 C8orf13-BLK gene variants were found. GCA patients were also stratified according to the presence of specific clinical features of the disease. In this regard, the allele A of the rs13277113 variant was overrepresented in patients with severe ischemic manifestations compared with patients without severe ischemic manifestations (p = 0.04; OR =1.65; 95% CI = 0.99-2.78). In conclusion, our results do not support a major implication of the C8orf13-BLK gene region in susceptibility to GCA. However, a potential implication of the rs13277113 variant in the development of severe ischemic complications may exist. Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156505     DOI: 10.1016/j.humimm.2010.02.016

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

1.  Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis.

Authors:  Ye Fan; Jin-Hui Tao; Li-Ping Zhang; Lian-Hong Li; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-12-09       Impact factor: 2.316

2.  Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein.

Authors:  Angélica M Delgado-Vega; Mikhail G Dozmorov; Manuel Bernal Quirós; Ying-Yu Wu; Belén Martínez-García; Sergey V Kozyrev; Johan Frostegård; Lennart Truedsson; Enrique de Ramón; María F González-Escribano; Norberto Ortego-Centeno; Bernardo A Pons-Estel; Sandra D'Alfonso; Gian Domenico Sebastiani; Torsten Witte; Bernard R Lauwerys; Emoke Endreffy; László Kovács; Carlos Vasconcelos; Berta Martins da Silva; Jonathan D Wren; Javier Martin; Casimiro Castillejo-López; Marta E Alarcón-Riquelme
Journal:  Ann Rheum Dis       Date:  2012-07       Impact factor: 19.103

3.  IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms.

Authors:  Joao Carlos Batista Liz; Fernanda Genre; Verónica Pulito-Cueto; Sara Remuzgo-Martínez; Diana Prieto-Peña; Ana Márquez; Norberto Ortego-Centeno; María Teresa Leonardo; Ana Peñalba; Javier Narváez; Luis Martín-Penagos; Lara Belmar-Vega; Cristina Gómez-Fernández; José A Miranda-Filloy; Luis Caminal-Montero; Paz Collado; Diego De Árgila; Patricia Quiroga-Colina; Esther F Vicente-Rabaneda; Ana Triguero-Martínez; Esteban Rubio; Manuel León Luque; Juan María Blanco-Madrigal; Eva Galíndez-Agirregoikoa; Javier Martín; Oreste Gualillo; Ricardo Blanco; Santos Castañeda; Miguel A González-Gay; Raquel López-Mejías
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

4.  B-cell lymphocyte kinase polymorphisms rs13277113, rs2736340, and rs4840568 and risk of autoimmune diseases: A meta-analysis.

Authors:  Chang Zeng; Cheng Fang; Hong Weng; Xiaoqing Xu; Tianyang Wu; Wenhua Li
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.